Primary Effusion Lymphoma (HHV-8)
Overview
Plain-Language Overview
Primary Effusion Lymphoma (PEL) is a rare type of cancer that affects the body's lymphatic system, which is part of the immune system. It primarily causes fluid buildup in body cavities such as the chest, abdomen, or around the heart, leading to symptoms like swelling and difficulty breathing. This condition is strongly linked to infection with a virus called human herpesvirus 8 (HHV-8). PEL mainly occurs in people with weakened immune systems, such as those with HIV/AIDS. The cancer cells grow in the fluid rather than forming solid tumors, which makes it unique compared to other lymphomas. The disease can progress quickly and requires specialized medical evaluation. Understanding the role of the virus and immune status is important in recognizing this illness.
Clinical Definition
Primary Effusion Lymphoma (PEL) is an aggressive B-cell lymphoma characterized by malignant lymphomatous effusions in body cavities without detectable solid tumor masses. It is universally associated with HHV-8 infection, which drives oncogenesis through viral oncogenes that promote cell proliferation and inhibit apoptosis. PEL predominantly affects immunocompromised patients, especially those with HIV/AIDS, and often co-infected with Epstein-Barr virus (EBV). The lymphoma cells typically express markers of activated B cells but lack typical B-cell antigens such as CD20. Clinically, PEL presents with pleural, peritoneal, or pericardial effusions causing symptoms related to fluid accumulation. The prognosis is poor due to rapid progression and resistance to conventional chemotherapy.
Inciting Event
HHV-8 infection of B cells initiates oncogenic transformation.
Severe immunosuppression (e.g., AIDS) triggers loss of immune control over HHV-8-infected cells.
Exposure to immunosuppressive drugs post-organ transplantation can precipitate lymphoma development.
Latency Period
Latency from HHV-8 infection to lymphoma development can be variable, often months to years.
In HIV patients, lymphoma typically arises after prolonged immunosuppression and low CD4 counts.
Post-transplant lymphomas may develop within months to a few years after immunosuppression initiation.
Diagnostic Delay
Presentation with pleural, pericardial, or peritoneal effusions without masses can delay suspicion of lymphoma.
Effusions may be initially attributed to infection or heart failure rather than malignancy.
Lack of typical lymphadenopathy or solid tumors leads to misdiagnosis or delayed biopsy.
Limited awareness of HHV-8 association and rarity of the disease contribute to delayed diagnosis.
Clinical Presentation
Signs & Symptoms
Dyspnea and chest discomfort due to large pleural or pericardial effusions
Fever and night sweats as systemic B symptoms
Weight loss and fatigue reflecting systemic illness
Nonproductive cough from pleural involvement
Signs of cardiac tamponade such as hypotension and jugular venous distension in pericardial effusion
History of Present Illness
Patients present with progressive dyspnea, chest discomfort, or abdominal distension due to effusions.
Symptoms develop subacutely over weeks to months with increasing fluid accumulation.
Systemic symptoms such as fever, night sweats, and weight loss are common.
Effusions are typically recurrent and refractory to standard drainage.
Past Medical History
HIV/AIDS with low CD4 count or history of poor antiretroviral adherence is common.
History of organ transplantation with chronic immunosuppressive therapy.
Prior diagnosis of Kaposi sarcoma or other HHV-8-associated diseases may be present.
Previous opportunistic infections indicating severe immunosuppression.
Family History
No well-established heritable syndromes are associated with primary effusion lymphoma.
Family history is generally non-contributory due to viral and immunologic etiology.
Rare familial clustering of HHV-8 infection may occur in endemic areas but does not directly cause lymphoma.
Physical Exam Findings
Dullness to percussion and decreased breath sounds over affected pleural or pericardial spaces due to effusions
Tachycardia and signs of cardiac tamponade if pericardial effusion is present
Peripheral edema and signs of right heart failure in advanced cases
Cachexia and generalized lymphadenopathy may be present in disseminated disease
Hepatosplenomegaly can be detected in some patients with systemic involvement
Diagnostic Workup
Diagnostic Criteria
Diagnosis of primary effusion lymphoma requires demonstration of lymphomatous effusion fluid containing large atypical lymphoid cells with immunophenotyping showing HHV-8 positivity by immunohistochemistry or PCR. The malignant cells usually express plasma cell markers (e.g., CD138) and lack typical B-cell markers like CD20. Detection of HHV-8 latent nuclear antigen-1 (LANA-1) in tumor cells is confirmatory. Imaging studies show effusions without solid masses, and cytology combined with flow cytometry and viral studies establishes the diagnosis.
Pathophysiology
Key Mechanisms
HHV-8 (Kaposi sarcoma-associated herpesvirus) latent infection drives oncogenesis by expressing viral oncogenes that promote B-cell proliferation and inhibit apoptosis.
Immunosuppression, especially in HIV/AIDS, impairs immune surveillance allowing unchecked HHV-8-driven lymphomagenesis.
Malignant cells are typically plasmablastic B cells with monoclonal immunoglobulin gene rearrangements and express viral IL-6 homolog promoting autocrine growth.
Cytokine dysregulation and angiogenesis contribute to the formation of malignant effusions without solid tumor masses.
The lymphoma cells often lack typical B-cell markers but express plasma cell markers such as CD138, reflecting differentiation state.
| Involvement | Details |
|---|---|
| Organs | Pleura is commonly involved, leading to pleural effusions and respiratory symptoms |
Pericardium involvement causes pericardial effusions and potential cardiac tamponade | |
Peritoneum involvement results in ascites and abdominal distension | |
| Tissues | Serous membranes (pleura, pericardium, peritoneum) are the primary sites of malignant effusion accumulation in this lymphoma |
Lymphoid tissue is involved as the site of malignant B cell proliferation and HHV-8 infection | |
| Cells | B cells are the malignant cell type in Primary Effusion Lymphoma, infected by HHV-8 and often co-infected with HIV |
T cells contribute to immune dysregulation and impaired tumor surveillance in this lymphoma | |
Endothelial cells may be involved due to HHV-8 tropism and contribute to effusion formation | |
| Chemical Mediators | HHV-8 viral proteins such as LANA promote oncogenesis by inhibiting tumor suppressors and activating proliferation pathways |
Cytokines like IL-6 and VEGF are elevated, promoting malignant cell growth and effusion accumulation | |
HIV viral proteins indirectly facilitate lymphoma development by causing immunosuppression |
Treatments
Pharmacological Treatments
Combination chemotherapy (e.g., CHOP regimen)
- Mechanism:
Cytotoxic agents induce apoptosis and inhibit proliferation of malignant B cells in Primary Effusion Lymphoma
- Side effects:
Myelosuppression
Nausea and vomiting
Cardiotoxicity
Peripheral neuropathy
- Clinical role:
First-line
Antiretroviral therapy (ART)
- Mechanism:
Suppresses HIV replication, improving immune function and reducing HHV-8-driven lymphomagenesis
- Side effects:
Hepatotoxicity
Lipodystrophy
Hyperlipidemia
- Clinical role:
Adjunctive
Rituximab
- Mechanism:
Monoclonal antibody targeting CD20 on B cells, promoting immune-mediated cytotoxicity
- Side effects:
Infusion reactions
Infections
Hypersensitivity
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Drainage of malignant effusions to relieve symptoms and improve respiratory or cardiac function
Supportive care including management of HIV infection and opportunistic infections
Radiation therapy may be considered for localized disease control in refractory cases
Prevention
Pharmacological Prevention
Antiretroviral therapy (ART) to maintain immune function in HIV-positive patients
Prophylactic antimicrobials to prevent opportunistic infections in immunocompromised hosts
Chemoprophylaxis with antivirals targeting HHV-8 is not established but under investigation
Early initiation of chemotherapy upon diagnosis to prevent effusion progression
Use of corticosteroids to reduce inflammation and effusion formation in select cases
Non-pharmacological Prevention
Regular HIV screening and early ART initiation to prevent severe immunosuppression
Avoidance of immunosuppressive therapies unless absolutely necessary in high-risk patients
Routine imaging surveillance in high-risk patients to detect effusions early
Safe sex practices to reduce transmission of HHV-8 and HIV
Prompt drainage of effusions to prevent complications such as tamponade
Outcome & Complications
Complications
Cardiac tamponade from pericardial effusion causing hemodynamic instability
Respiratory failure due to large pleural effusions impairing lung expansion
Sepsis from secondary infections in immunocompromised hosts
Tumor lysis syndrome following chemotherapy initiation
Progression to disseminated lymphoma with multiorgan involvement
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Primary Effusion Lymphoma (HHV-8) versus Diffuse Large B-Cell Lymphoma (DLBCL)
Primary Effusion Lymphoma (HHV-8) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
Large atypical lymphoid cells confined to body cavity effusions without solid tumor masses | Sheets of large atypical B cells with variable morphology, often forming solid tumor masses |
Usually negative for pan-B cell markers but positive for plasma cell markers CD138 and HHV-8 latent nuclear antigen | Positive for pan-B cell markers CD19, CD20, CD79a |
Presence of HHV-8 latent nuclear antigen detected by immunohistochemistry or PCR | Absence of HHV-8 DNA or latent nuclear antigen in tumor cells |
Primary Effusion Lymphoma (HHV-8) versus Kaposi Sarcoma
Primary Effusion Lymphoma (HHV-8) | Kaposi Sarcoma |
|---|---|
Large lymphoid cells in effusion without spindle cell morphology | Spindle cell proliferation with slit-like vascular spaces and extravasated red blood cells |
HHV-8 infection localized to lymphoid tumor cells | HHV-8 infection localized to endothelial spindle cells |
Primary lymphomatous effusions without cutaneous lesions | Cutaneous and mucosal vascular lesions with possible visceral organ involvement |
Primary Effusion Lymphoma (HHV-8) versus Plasmablastic Lymphoma
Primary Effusion Lymphoma (HHV-8) | Plasmablastic Lymphoma |
|---|---|
Expression of plasma cell markers with consistent HHV-8 positivity | Strong expression of plasma cell markers CD138 and MUM1 with variable CD20 expression |
Strongly associated with HHV-8 infection, often in HIV-positive patients | Commonly associated with HIV infection but usually HHV-8 negative |
Effusion-based lymphoma without solid tumor formation | Solid tumor masses in oral cavity or lymph nodes |
Primary Effusion Lymphoma (HHV-8) versus Tuberculous Pleural Effusion
Primary Effusion Lymphoma (HHV-8) | Tuberculous Pleural Effusion |
|---|---|
Presence of HHV-8 DNA in lymphoma cells, no acid-fast bacilli | Presence of Mycobacterium tuberculosis detected by acid-fast stain or culture |
Malignant effusion with atypical lymphoid cells and positive HHV-8 immunostaining | Exudative pleural fluid with lymphocytic predominance and elevated adenosine deaminase |
Rapidly progressive effusion related to lymphoma without infectious symptoms | Subacute to chronic pleural symptoms with systemic signs of infection |
Primary Effusion Lymphoma (HHV-8) versus Chylous Effusion due to Lymphatic Obstruction
Primary Effusion Lymphoma (HHV-8) | Chylous Effusion due to Lymphatic Obstruction |
|---|---|
Serous or hemorrhagic effusion with malignant lymphoid cells, no chylomicrons | Milky pleural fluid with high triglycerides and chylomicrons |
No lymphatic obstruction; effusion due to lymphoma infiltration | Lymphatic obstruction or trauma visible on imaging without malignant masses |
Rapidly accumulating malignant effusion | Chronic effusion related to lymphatic leakage |